Engineering the Tumor Microenvironment During Cell Manufacturing

Engineering the Tumor Microenvironment During Cell Manufacturing

Introduction

Cell therapies are typically manufactured under standardized ex vivo conditions designed to maximize expansion and viability. However, these conditions often differ substantially from the environments that therapeutic cells encounter after infusion, particularly within solid tumors.

The tumor microenvironment (TME) is characterized by hypoxia, nutrient limitation, and metabolic stress, all of which can impair immune cell function. Increasingly, research suggests that exposing cells to more physiologically relevant conditions during manufacturing may improve their ability to function after infusion.

This concept, engineering the cellular environment during manufacturing to better match in vivo conditions, represents a growing area of interest in cell therapy development.

The Mismatch Between Manufacturing and In Vivo Environments

Standard cell culture conditions typically involve:

• atmospheric oxygen (~21% O₂)

• nutrient-rich media

• static two-dimensional culture with no bioreactor-style mechanical inputs

In contrast, solid tumor microenvironments often exhibit:

• low oxygen levels (~0.2–4% O₂; median values typically below 2%)

• nutrient deprivation

• accumulation of metabolic by-products such as lactate

It is worth noting that the mismatch extends beyond tumors specifically: normal peripheral tissue oxygen (physoxia) averages around 5% and ranges from approximately 3% to 7.4%, meaning standard culture conditions are metabolically mismatched with all in vivo environments, not only tumors (McKeown, 2014). This mismatch can result in T cells that are optimized for growth in vitro but less prepared for the metabolic constraints they encounter in vivo (Vaupel & Mayer, 2007; McKeown, 2014).

As a result, cells expanded under conventional conditions may experience rapid functional decline following infusion into tumors.

Hypoxia as a Key Environmental Signal

Hypoxia is one of the most defining features of solid tumors and plays a central role in shaping immune cell metabolism and function. Low oxygen levels stabilize hypoxia-inducible factors (HIFs), which activate transcription of genes encoding glucose transporters, glycolytic enzymes, pyruvate dehydrogenase kinase, and lactate dehydrogenase, collectively shifting cells away from oxidative phosphorylation and toward anaerobic glycolysis (Semenza, 2012).

In T cells, hypoxia can influence:

• metabolic pathway selection

• differentiation state

• effector function and persistence

The effects of hypoxia on T cells are highly context-dependent. Importantly, research has shown that hypoxia alone does not necessarily drive T cell dysfunction; it is the combination of continuous stimulation under hypoxia that rapidly leads to exhaustion, mediated by Blimp-1-driven repression of mitochondrial biogenesis (Scharping et al., 2021). This distinction has direct implications for manufacturing: applying hypoxic conditions during active stimulation phases carries a different risk profile than applying them during rest or memory-formation phases.

Controlled hypoxic exposure at appropriate stages of manufacturing may therefore precondition T cells to better tolerate hypoxic tumor environments, though the timing, intensity, and duration of exposure require careful optimization (Corrado et al., 2022).

Environmental Conditioning and Metabolic Programming

Beyond oxygen levels, multiple environmental factors can influence T cell metabolism during manufacturing, including:

• nutrient availability (e.g., glucose, amino acids)

• cytokine signaling

• pH and metabolite accumulation

• physical parameters such as pressure and gas composition

These variables shape metabolic programming, which in turn influences differentiation into effector or memory-like states.

For example, conditions that promote mitochondrial function and metabolic flexibility may support the generation of T cells with improved persistence. Conversely, overly stimulatory conditions may drive terminal differentiation and reduce long-term efficacy (Buck et al., 2015). Engineering these parameters in a controlled manner offers a potential strategy for improving therapeutic performance.

Toward Physiologically Relevant Manufacturing Systems

There is growing interest in developing manufacturing systems that provide precise control over oxygen, pressure, and environmental parameters to better replicate in vivo conditions during cell expansion.

Such systems aim to more closely replicate aspects of the tumor microenvironment or lymphoid tissues, enabling the generation of cells that are better adapted to their intended therapeutic context. This approach represents a shift from maximizing expansion alone to optimizing functional fitness and persistence.

Implications for Next-Generation Cell Therapies

As cell therapies expand into solid tumor indications, overcoming the challenges of the tumor microenvironment becomes increasingly important. Engineering the manufacturing environment offers several potential advantages:

• improved persistence of therapeutic cells

• enhanced resistance to metabolic stress

• better functional performance in hypoxic conditions

By integrating environmental conditioning into manufacturing workflows, developers may be able to produce more effective and durable cell therapies.

Looking Forward

The tumor microenvironment presents one of the most significant barriers to effective cell therapy in solid tumors. Bridging the gap between in vitro manufacturing conditions and in vivo environments, including the gap between 21% culture oxygen and the physoxic baseline of normal tissues, is an important step toward improving therapeutic outcomes.

Advances in immunometabolism and bioprocessing technologies are enabling new approaches to environmental control during cell expansion, opening the door to more physiologically informed manufacturing strategies.

As the field evolves, engineering the cellular environment, with careful attention to the timing and context of hypoxic exposure, nutrient conditions, and stimulation protocols, may become a central component of next-generation cell therapy development.

Frequently Asked Questions

Why does the tumor microenvironment matter for cell therapy?

The tumor microenvironment contains conditions such as low oxygen, limited nutrients, and metabolic stress that can impair immune cell function. These factors can reduce the effectiveness and persistence of therapeutic cells.

What is environmental conditioning in cell therapy manufacturing?

Environmental conditioning refers to controlling factors such as oxygen levels, nutrients, and physical parameters during cell expansion to influence T cell metabolism and function.

Can hypoxia improve T cell therapies?

In some contexts, controlled exposure to low oxygen levels during manufacturing may help T cells adapt to hypoxic tumor environments. However, outcomes depend on how hypoxia is applied.

How does manufacturing affect T cell persistence?

Manufacturing conditions influence metabolic programming and differentiation state. These factors determine whether T cells develop into short-lived effectors or long-lived memory-like cells.

What is the advantage of physiologically relevant manufacturing systems?

Systems that better mimic in vivo conditions may produce cells that are more resilient, metabolically adaptable, and effective after infusion.

References

Buck, M.D., O’Sullivan, D., & Pearce, E.L. (2015). T cell metabolism drives immunity. Journal of Experimental Medicine, 212(9), 1345–1360. [Corrected from “2017” in the original; the relevant review by these authors is the 2015 JEM paper.]

Corrado, M. et al. (2022). Targeting memory T cell metabolism to improve immunity. Journal of Clinical Investigation. [Journal attribution to be independently verified.]

McKeown, S.R. (2014). Defining normoxia, physoxia and hypoxia in tumours. The British Journal of Radiology, 87(1035), 20130676.

Scharping, N.E. et al. (2021). Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nature Immunology, 22, 205–215.

Semenza, G.L. (2012). Hypoxia-inducible factors in physiology and medicine. Cell, 148(3), 399–408.

Vaupel, P., & Mayer, A. (2007). Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Reviews. [Note: original cited as “Cancer and Metastasis Reviews”; correct journal name is Cancer Metastasis Reviews.]

Explore AVATAR Environmental Control Platforms

Engineering the cellular environment during manufacturing is a powerful approach to improving cell therapy outcomes. AVATAR™ systems enable precise control of oxygen, pressure, and metabolic conditions across research and GMP workflows.

Explore AVATAR Technology →